Visual function in multiple sclerosis patients treated with Fingolimob during two years of follow‐up

Abstract

PurposeTo evaluate visual function changes in multiple sclerosis (MS) patients treated with Fingolimob during two years.MethodsA total of 31 eyes of 16 MS patients that were going to start Fingolimob treatment were included. All of them underwent an ophtalmic examination including best corrected visual acuity (BCVA) using ETDRS optotype with 100%, 2,5% and 1.25% contrast; contrast sensitivity using CSV 100 E and Pelli‐Robson tests and cromatic vision using Farsworth and Lanthony D15 tests. Quality of life was evaluated by the MSQOL questionnaire. The same protocol was repeated 2 years later.ResultsA significant reduction of visual acuity was observed after two years of follow‐ up in 2.5% (0.33 ± 0.023 vs 0.39 ± 0.16; p < 0.001) and 1.25% (0.43 ± 0.05 vs 0.54 ± 0.22; p < 0.001) contrasts. All CSV frequencies showed a significant decrease except 18 cpd (3 cpd: 1.78 vs 1.73 ± 0.17; 6 cpd: 1.94 ± 0.17 vs 1.85 ± 0.24; 12 cpd: 1.69 vs 1.39 ± 0.37; p < 0.001). A progresive reduction in chromatic vision (Farnsworth and Lanthony test, p < 0.001) was also found. MSQOL‐54 questionnarie result was significatly lower after two years in physical (p = 0.023) and mental (p = 0.032) health sections.ConclusionsMS patients treated with Fingolimob present progressive changes in visual acuity, contrast sensivity, and chromatic vision. Visual function tests may be an useful tool to evaluate the progression of neurodegenerative diseases and treatment effectiveness.